Small cell lung cancer (SCLC) is characterized by early metastasis, intrinsic chemoradiation resistance, and tumor recurrence. Besides the lack of potentially targetable oncogenic drivers, therapeutic advancements are also hindered by the scarcity of surgically resected tissue specimens ideal for pr …

AAADV Workshop Foundation Unveils Program for 2026 Workshop, Convening the Architects of Modern…

Science sleuth’s findings raise questions for researchers working to improve the reliability of commercial antibodies.

How early-career researchers can strengthen their track record, boost their research proposal and assess institutional fit.

Mallard de La Varende et al. demonstrate that gut dysbiosis impairs tumor immunosurveillance through the gut-liver axis, causing subclinical cholestasis and immunotherapy resistance in tumors distant from gastrointestinal and hepatic tissues. Gut dysbiosis triggers plasma elevation of γ-glutamyl transferase, increase in TCDCA in humans (TMCA in mice), and drop in sMAdCAM-1 levels.

Why do some cancers fail treatment from the very beginning? In this episode of the ARTNet Podcast, Dr. David Goodrich speaks with Dr. Vlad C. Sandulache of Baylor College of Medicine about emerging re...

Upcoming Webinars

RegistrationPlease ensure you also submit information under "Project Submission" as a Project Lead or Project Seeker.

OverviewSignificant challenges exist in understanding and tackling tumor heterogeneity across the initiation-progression-resistance spectrum. Central to this challenge is cellular plasticity, which co...

FET fusion oncoproteins subvert genome maintenance by impairing ATM activity, bridging two key fields-oncogene biology and DNA repair-and proposing ATR inhibition as a targeted therapeutic approach fo...

FET fusion oncoproteins subvert genome maintenance by impairing ATM activity, bridging two key fields-oncogene biology and DNA repair-and proposing ATR inhibition as a targeted therapeutic approach fo...

<p>Why do cancer treatments work for some patients at first, only to stop working later? In the premiere episode of the <a rel="noopener noreferrer nofollow" href="https://www.nciartnet.org?utm_source...

NIH policy allows for administrative supplements within the scope of the peer-reviewed and approved project to support costs and activities unforeseen at the time of the parent grant award. We provide...

Despite recent treatment advances, most patients with acute myeloid leukemia (AML)—especially those ineligible for intensive chemotherapy—ultimately relapse due to adaptive resistance to therapies lik...

While therapies targeting type I BRAF mutations have been developed, there are limited options for those with type II and III mutations. Here, the authors identify a subset of BRAF-mutant non-small ce...

Photoproximity labeling proteomics (PLP) methods have recently shown that cell surface receptors can form lateral interactome networks. Here, we present a paired set of PLP workflows that dynamically track neighborhood changes for oncogenic epidermal growth factor receptor (EGFR) over time, both out …

Scientific Data - Biomedical Data Manifest: A lightweight data documentation mapping to increase transparency for AI/ML

The upcoming NCI CAP-IT Summit is set to convene a diverse mix of participants, including senior leaders, experts, and emerging talents such as junior investigators and trainees, all dedicated to the ...

Photoproximity labeling proteomics (PLP) methods have recently shown that cell surface receptors can form lateral interactome networks. Here, we present a paired set of PLP workflows that dynamically track neighborhood changes for oncogenic epidermal growth factor receptor (EGFR) over time, both out …

Lineage plasticity is a cancer hallmark that drives disease progression and treatment resistance^1,2. Plasticity is often mediated by epigenetic mechanisms that may be reversible; however, there are few examples of such reversibility. In castration-resistant prostate cancer (CRPC), plastic …

Drug resistance is a leading cause of cancer treatment failure and tumor recurrence. Identifying new methods that eliminate life-threatening drug-resistant cancer cells (DRCs) can enhance tumor cell eradication and improve patient outcomes. Here we report that human non-small cell lung cancer (NSCLC …

In partnership with the National Cancer Institute (NCI), SITC is pleased to launch a new series of ten computational immuno-oncology webinars that will focus specifically on advanced methods and clini...